Vadastuximab talirine

Vadastuximab talirine

Vadastuximab talirine is an antibody-drug conjugate (ADC) designed for the treatment of acute myeloid leukemia (AML). It is composed of a monoclonal antibody targeting the CD33 antigen, which is commonly expressed on the surface of AML cells, linked to a cytotoxic agent.

Mechanism of Action

Vadastuximab talirine works by specifically binding to the CD33 antigen on the surface of AML cells. Upon binding, the ADC is internalized into the cell, where the cytotoxic agent is released. This agent then induces DNA damage, leading to cell death. The targeted approach aims to minimize damage to normal, healthy cells, thereby reducing the side effects typically associated with conventional chemotherapy.

Development and Clinical Trials

Vadastuximab talirine was developed by Seattle Genetics. It has undergone various phases of clinical trials to evaluate its safety and efficacy in patients with AML. The results from these trials have been mixed, with some showing promising outcomes in terms of remission rates and overall survival, while others have raised concerns about potential side effects and toxicity.

Side Effects

Common side effects of vadastuximab talirine include neutropenia, thrombocytopenia, and anemia. More severe side effects can include hepatotoxicity and veno-occlusive disease (VOD). Due to these potential risks, the use of vadastuximab talirine is typically reserved for patients who have not responded to other treatments or who are ineligible for other forms of therapy.

Current Status

As of the latest updates, vadastuximab talirine is not yet approved by the Food and Drug Administration (FDA) for general use. Ongoing research and additional clinical trials are being conducted to further assess its safety and efficacy.

Related Pages

• Acute myeloid leukemia
• Antibody-drug conjugate
• CD33
• Seattle Genetics
• Chemotherapy
• Neutropenia
• Thrombocytopenia
• Anemia
• Hepatotoxicity
• Veno-occlusive disease

See Also

• List of investigational antineoplastic agents

   This article is a medical stub. You can help WikiMD by expanding it!